Alzheimer's disease
Bernie Sanders says price of Alzheimer’s treatment is unconscionable, calls on HHS to take action
Sen. Bernie Sanders (I-VT) arrives to the U.S. Capitol Building on June 01, 2023 in Washington, DC. Anna Moneymaker | Getty Images Sen. Bernie Sanders on Wednesday called on the U.S. Health and Human Services Department to take action to ensure seniors can actually afford the expensive Alzheimer’s treatment Leqembi. Sanders, who chairs the Senate […]
Read More
Medicare details plan to cover Alzheimer’s treatments
An MRI scan of an Alzheimer’s patient’s brain GSO Images | Getty Images Medicare Part B will cover Alzheimer’s treatments that receive Food and Drug Administration approval, according to the federal agency that administers the program for seniors. Anyone who has Medicare Part B and meets “eligibility criteria” will be covered for new antibody treatments […]
Read More
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
The Alzheimer’s drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | Reuters The new Alzheimer’s antibody treatment Leqembi could cost Medicare up to $5 billion per year, according to research published in a leading medical journal this week. Medicare would spend about $2 billion per year […]
Read More
FDA commissioner praises Eli Lilly Alzheimer’s treatment results
FDA Commissioner Dr. Robert Califf speaks at an event celebrating hearing aids being available over the counter at a Walgreens in Washington, D.C., Oct. 19, 2022. Nathan Posner | Anadolu Agency | Getty Images Food and Drug Commissioner Dr. Robert Califf praised results Eli Lilly announced Wednesday that a clinical trial showed its Alzheimer’s treatment […]
Read More
Eli Lilly Alzheimer’s treatment donanemab slowed ailment progression in clinical trial
An Eli Lilly and Organization pharmaceutical production plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Mike Segar | Reuters The Alzheimer’s treatment method donanemab, which is manufactured by Eli Lilly, appreciably slowed development of the brain-robbing disease, according to scientific demo info introduced Wednesday by the firm. Individuals who […]
Read More
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli Lilly as they both attempt to bring an Alzheimer’s drug to the market, Biogen’s CEO said Tuesday. “I think it will be good if there are […]
Read More
Veterans Health Administration will cover Alzheimer’s treatment Leqembi, Eisai says
The Veterans Health Administration will cover Eisai and Biogen‘s Alzheimer’s treatment Leqembi, the companies announced Monday. In a statement, drugmaker Eisai said veterans in the early stages of the disease who meet VHA criteria are eligible for coverage of Leqembi. The decision by VHA stands in contrast with Medicare, which has declined to cover the […]
Read More
Here’s where to look for the next developments in the fight against Alzheimer’s disease
Biogen and its partner, Japanese drugmaker Eisai , earlier this month received accelerated approval from the Food and Drug Administration for Leqembi, a monoclonal antibody to treat Alzheimer’s disease. Although Biogen shares are trading higher in the wake of this development , they are only up 4% or so year to date. To some degree, […]
Read More
A brain qualified shares his 7 ‘hard rules’ for boosting memory and fighting off dementia
The average human mind shrinks by somewhere around 5% for every 10 years following the age of 40. This can have a big impression on memory and aim. What is actually far more, brain ailments are on the rise. In 2020, 54 million persons all over the world experienced Alzheimer’s illness or other dementias, and […]
Read More
Goldman upgrades Biogen, says it’s poised to address early Alzheimer’s market next year
Biogen shares have a lot more potential upside for investors thanks to positive new data around the company’s early Alzheimer’s drug, Goldman Sachs said Wednesday. The firm upgraded Biogen to a buy from neutral and increased its price target on shares to $370, about 35% from where they closed on Tuesday. The upgrade followed the […]
Read More